Patent classifications
A61K31/4525
DOSAGE REGIME WITH ESKETAMINE FOR TREATING NEUROPSYCHIATRIC OR NEUROLOGICAL CONDITIONS
The present invention provides a method for safe and efficacious administration of esketamine.
Oxaborole esters and uses thereof
The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.
Oxaborole esters and uses thereof
The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.
Composition and method for treatment of depression and psychosis in humans
This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.
Composition and method for treatment of depression and psychosis in humans
This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.
Composition and method for treatment of depression and psychosis in humans
This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.
NUTRACEUTICAL FORMULATIONS TO PREVENT, TREAT, AND INHIBIT EXCESS CYTOKINES, SARS-CoV-2 SPIKE PROTEINS, AND mRNA VACCINE SPIKE PROTEINS
Combinations of cannabinoids, vitamins, trace elements, bioactive components, bioflavonoid polyphenols, proteolytic enzymes, amino acids, and antioxidants which work independently and synergistically for the prevention, treatment, and inhibition of excess cytokines caused by the immune response to extreme viral and bacterial infections, including the inhibition of COVID-19, Rhinovirus and/or other virus spike proteins and mRNA vaccine spike proteins from attaching to body organ cells, penetrating cell membranes, and the replication of virus particles and spike proteins inside the cells. Inhibition of inflammation and prevention of long-term side effects, health issues (long-haulers), and disease caused by the SARS-CoV-2 and its variants, Rhinovirus, other viruses, bacteria, and mRNA vaccines are provided by the nutraceutical compositions. Specific combinations of these compounds work synergistically to increase the efficacy of the independent nutraceuticals in treatment.
NUTRACEUTICAL FORMULATIONS TO PREVENT, TREAT, AND INHIBIT EXCESS CYTOKINES, SARS-CoV-2 SPIKE PROTEINS, AND mRNA VACCINE SPIKE PROTEINS
Combinations of cannabinoids, vitamins, trace elements, bioactive components, bioflavonoid polyphenols, proteolytic enzymes, amino acids, and antioxidants which work independently and synergistically for the prevention, treatment, and inhibition of excess cytokines caused by the immune response to extreme viral and bacterial infections, including the inhibition of COVID-19, Rhinovirus and/or other virus spike proteins and mRNA vaccine spike proteins from attaching to body organ cells, penetrating cell membranes, and the replication of virus particles and spike proteins inside the cells. Inhibition of inflammation and prevention of long-term side effects, health issues (long-haulers), and disease caused by the SARS-CoV-2 and its variants, Rhinovirus, other viruses, bacteria, and mRNA vaccines are provided by the nutraceutical compositions. Specific combinations of these compounds work synergistically to increase the efficacy of the independent nutraceuticals in treatment.
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
- Mark Thomas Miller ,
- Corey Anderson ,
- Vijayalaksmi Arumugam ,
- Brian Richard Bear ,
- Hayley Marie Binch ,
- Jeremy J. Clemens ,
- Thomas Cleveland ,
- Erica Conroy ,
- Timothy Richard Coon ,
- Bryan A. Frieman ,
- Peter Diederik Jan Grootenhuis ,
- Raymond Stanley Gross ,
- Sara Sabina Hadida-Ruah ,
- Haripada Khatuya ,
- Pramod Virupax Joshi ,
- Paul John Krenitsky ,
- Chun-Chieh Lin ,
- Gulin Erdogan Marelius ,
- Vito Melillo ,
- Jason McCartney ,
- Georgia McGaughey Nicholls ,
- Fabrice Jean Denis Pierre ,
- Alina Silina ,
- Andreas P. Termin ,
- Johnny Uy ,
- Jinglan Zhou
The present invention features a compound of formula I:
##STR00001##
or a pharmaceutically acceptable salt thereof, where R.sub.1, R.sub.2, R.sub.3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
- Mark Thomas Miller ,
- Corey Anderson ,
- Vijayalaksmi Arumugam ,
- Brian Richard Bear ,
- Hayley Marie Binch ,
- Jeremy J. Clemens ,
- Thomas Cleveland ,
- Erica Conroy ,
- Timothy Richard Coon ,
- Bryan A. Frieman ,
- Peter Diederik Jan Grootenhuis ,
- Raymond Stanley Gross ,
- Sara Sabina Hadida-Ruah ,
- Haripada Khatuya ,
- Pramod Virupax Joshi ,
- Paul John Krenitsky ,
- Chun-Chieh Lin ,
- Gulin Erdogan Marelius ,
- Vito Melillo ,
- Jason McCartney ,
- Georgia McGaughey Nicholls ,
- Fabrice Jean Denis Pierre ,
- Alina Silina ,
- Andreas P. Termin ,
- Johnny Uy ,
- Jinglan Zhou
The present invention features a compound of formula I:
##STR00001##
or a pharmaceutically acceptable salt thereof, where R.sub.1, R.sub.2, R.sub.3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.